B-(2-甲基-3-噻吩)硼酸 | 177735-10-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 中文名称: B-(2-甲基-3-噻吩)硼酸
• 英文名称: (2-methylthiophen-3-yl)boronic acid
• CAS: 177735-10-3
• 化学式: C₅H₇BO₂S
• 分子量: 141.986
• InChiKey: IOZXRAJFXAKLNI-UHFFFAOYSA-N

物化性质

• 沸点：
  299.5±42.0 °C(Predicted)
• 密度：
  1.25±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.26
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  68.7
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Methylthiophene-3-boronic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Methylthiophene-3-boronic acid
CAS number: 177735-10-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H7BO2S
Molecular weight: 142.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  B-(2-甲基-3-噻吩)硼酸 在 2,2'-联吡啶 、 silver carbonate 、 palladium dichloride 作用下， 以 间二甲苯 为溶剂， 反应 13.0h， 生成 3-(3,3,4,4,5,5-hexafluoro-2-(2-methyl-5-phenyl(3-thienyl))cyclopent-1-enyl)-2-methyl-5-phenylthiophene
  参考文献：
  名称：

  通过钯催化的区域选择性直接芳基化作用的简单二噻吩乙烯的功能化

  摘要：

  在钯催化下，二芳基乙烯的噻吩基与各种芳基碘化物的直接芳基化有效地提供了芳基化的二噻吩基乙烯。该协议还合成了不对称取代的二噻吩基乙烯。该方法允许从简单的二噻吩基乙烯的单个底物快速获得各种芳基取代的二噻吩基乙烯。

  DOI：

  10.1021/ol2026069
• 作为产物：
  描述：

  3-溴-2-甲基噻吩 在 正丁基锂 、 硼酸三异丙酯 、 盐酸 作用下， 以 四氢呋喃 、 正己烷 、 水 为溶剂， 反应 1.33h， 以65%的产率得到B-(2-甲基-3-噻吩)硼酸
  参考文献：
  名称：

  Synthetic protocol for diarylethenes through Suzuki–Miyaura coupling

  摘要：

  通过 1,2-二氯六氟环戊烯与芳基硼酸和酯的铃木宫浦偶联反应合成了多种二元噻吩。可以加入具有氰基和酯官能团等各种取代基的噻吩。

  DOI：

  10.1039/c1cc12020d

文献信息

• [EN] SUBSTITUTED PYRROLOPYRIDINE-DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRROLOPYRIDINE SUBSTITUÉS
  申请人：BAYER PHARMA AG

  公开号：WO2019016071A1

  公开（公告）日：2019-01-24

  The present invention relates to protein-inhibitory substituted pyrrolopyridine derivatives of formula (I), in which A, X, R1, R2a, R2b, R3a, R3b, R4a and R4b are as defined herein, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, repectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients. The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control.

  本发明涉及式(I)的蛋白抑制取代吡咯吡啶衍生物，其中A、X、R1、R2a、R2b、R3a、R3b、R4a和R4b如本文所定义，以及包含根据本发明的化合物的药物组合物和药物组合物，以及创新化合物的预防和治疗用途，分别用于制造用于治疗或预防疾病的药物组合物，特别是用于肿瘤性疾病、癌症或与MAP4K1信号异常相关的其他疾病的治疗或预防，作为单一药剂或与其他活性成分组合使用。本发明还涉及用途，分别用于制造用于治疗或预防良性增生、动脉粥样硬化疾病、败血症、自身免疫性疾病、血管疾病、病毒感染、神经退行性疾病、炎症性疾病、动脉粥样硬化疾病和男性生育控制的蛋白抑制剂的药物组合物。
• Selective Introduction of Organic Groups to C60 and C70 Using Organoboron Compounds and Rhodium Catalyst: A New Synthetic Approach to Organo(hydro)fullerenes
  作者：Masakazu Nambo、Yasutomo Segawa、Atsushi Wakamiya、Kenichiro Itami

  DOI：10.1002/asia.201000583

  日期：2011.2.1

  A Rh‐catalyzed reaction of C60 and C70 with organoboron compounds is described. This new catalytic method enables introduction of various organic groups onto C60 and C70. [Rh(cod)(MeCN)2]BF4 proved to be the most effective catalyst in terms of productivity and selectivity. The reaction generally proceeds with a high regioselectivity and in a mono‐addition selective manner. It was found that water is

  描述了C 60和C 70与有机硼化合物的Rh催化反应。这种新的催化方法能够将各种有机基团引入C 60和C 70上。就产率和选择性而言，[Rh（cod）（MeCN）2 ] BF 4被证明是最有效的催化剂。反应通常以高区域选择性和单加成选择性的方式进行。发现水是促进反应的必要添加剂。通过X射线晶体结构分析，我们已经确认了C 70的有机金属基加氢芳基化反应的位点首次。可以合成各种功能性富勒烯，例如富勒烯标记的氨基酸和富勒烯封端的π系统。联苯连接的C 60的X射线晶体结构揭示了利用CH-π相互作用使巴基球组织良好的有趣机会。
• Photoinduced Four-State Three-Step Ordering Transformation of Photochromic Terthiophene at a Liquid/Solid Interface Based on Two Principles: Photochromism and Polymorphism
  作者：Soichi Yokoyama、Takashi Hirose、Kenji Matsuda

  DOI：10.1021/acs.langmuir.5b01404

  日期：2015.6.16

  polymorphism. By controlling photochromism and polymorphism among four states made of three photochemical isomers, four-state three-step transformation was achieved by in situ photoirradiation from a solution of the closed-ring isomer (no ordering) into the ordering composed of the open-ring isomer (ordering α and β) followed by the orderings composed of the annulated isomer (ordering γ).

  我们已经通过在三氯苯（TCB）/高度取向的热解石墨（HOPG）界面上扫描隧道显微镜（STM）研究了光致变色三噻吩衍生物的光诱导有序转化。噻吩的开环和环状异构体形成具有不同图案的二维分子有序，而闭环异构体则不形成任何有序。开环异构体的顺序表现出多态性，这取决于上清液的浓度。在紫外光照射到开环异构体或闭环异构体的溶液上时，不可逆地形成由环状异构体组成的有序。在可见光照射或热刺激闭环异构体时，由于多态性，形成了由开环异构体组成的两种多晶型物。从闭环异构体的溶液进行原位光辐照（无序），到由开环异构体组成的有序（α和β的顺序），然​​后是由环状异构体组成的有序（γ的顺序）。
• Imidazopyridazine Compounds
  申请人：Barbosa Heather Janelle

  公开号：US20080113978A1

  公开（公告）日：2008-05-15

  The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I): pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.

  本发明涉及一种新的取代咪唑[1,2-b]吡嗪化合物(I)，其药物组成物以及将这些化合物作为促肾上腺皮质激素释放因子1(CRF1)受体拮抗剂用于治疗精神障碍和神经系统疾病的用途。
• Imidazopyridazine compounds
  申请人：Eli Lilly and Company

  公开号：US07612067B2

  公开（公告）日：2009-11-03

  The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I): pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.

  本发明涉及新型的取代咪唑[1,2-b]吡啶嗪化合物（I），其制药组合物以及将此类化合物用作促肾上腺皮质激素释放因子1（CRF1）受体拮抗剂治疗精神障碍和神经疾病。